Core Insights - Cortigent is a leading developer of brain interface devices utilizing precision neurostimulation technology, with a focus on treating blindness and improving motor recovery in stroke patients [1][3] Group 1: Orion Cortical Stimulation System - The Orion cortical stimulation system is designed to treat common forms of blindness and has successfully completed a six-year Early Feasibility Study, showing promising safety and efficacy results [1][3] - The investigational Orion system features a compact design with one of the smallest and highest-count micro-electrode neurostimulators, implanted on the visual cortex to deliver controlled electrical charges that create visual perception [2][3] - The system includes an implantable pulse generator with 60 outputs and a 60-electrode cortical surface array, demonstrating safety and functionality for over 17 years in previous devices [2] Group 2: Company Background and Technology - Cortigent, a subsidiary of Vivani Medical, is focused on developing brain implant devices to restore critical body functions, leveraging a patent-protected precision neurostimulation technology platform [3] - The company’s predecessor, Second Sight Medical Products, previously marketed the Argus II, the first FDA-approved device for treating a rare form of blindness, which has helped hundreds of patients achieve meaningful visual perception [3] - Cortigent is also applying its technology to enhance recovery of arm and hand motion in patients with paralysis due to stroke [3] Group 3: Upcoming Presentation - Cortigent will present an award-winning poster on the Orion Visual Cortical Prosthesis System at the North American Neuromodulation Society annual meeting in Las Vegas on January 23, 2026 [1]